Reviva Pharmaceuticals Holdings, Inc. Repayments of Short-term Debt
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Repayments of Short-term Debt of $262.78 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfShortTermDebt · last filed 2026-08-12
- Reviva Pharmaceuticals Holdings, Inc. repayments of short-term debt for the quarter ending 2026-06-30 was $87.18K, a 21.50% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. repayments of short-term debt for the quarter ending 2026-03-31 was $175.60K, a 24.91% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. repayments of short-term debt for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. repayments of short-term debt for the quarter ending 2025-09-30 was $113.25K, a 9.04% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. repayments of short-term debt for fiscal 2025 was $458.15K, a 11.68% decline from fiscal 2024.
- Reviva Pharmaceuticals Holdings, Inc. repayments of short-term debt for fiscal 2024 was $518.75K, a 22.28% decline from fiscal 2023.
- Reviva Pharmaceuticals Holdings, Inc. repayments of short-term debt for fiscal 2023 was $667.50K.
- Reviva Pharmaceuticals Holdings, Inc. repayments of short-term debt for fiscal 2022 was $0.00.
| Period end | Repayments of Short-term Debt 3 month | Repayments of Short-term Debt 6 month | Repayments of Short-term Debt 9 month | Repayments of Short-term Debt 12 month |
|---|---|---|---|---|
| 2026-06-30 | $87.18K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $262.78K 10-Q · filed 2026-08-12 | $262.78K derived: sum of 3 quarters · filed 2026-08-12 | $376.03K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $175.60K 10-Q · filed 2026-05-13 | $175.60K derived: sum of 2 quarters · filed 2026-05-13 | $288.85K derived: sum of 3 quarters · filed 2026-05-13 | $399.90K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $113.25K derived: sum of 2 quarters · filed 2026-03-30 | $224.30K derived: sum of 3 quarters · filed 2026-08-12 | $458.15K 10-K · filed 2026-03-30 |
| 2025-09-30 | $113.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $224.30K derived: sum of 2 quarters · filed 2026-08-12 | $458.15K 10-Q · filed 2025-11-13 | $644.90K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $111.05K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $344.91K 10-Q · filed 2026-08-12 | $531.66K derived: sum of 3 quarters · filed 2026-08-12 | $656.16K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $233.85K 10-Q · filed 2026-05-13 | $420.60K derived: sum of 2 quarters · filed 2026-05-13 | $545.10K derived: sum of 3 quarters · filed 2026-05-13 | $669.60K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $186.75K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $311.25K derived: sum of 2 quarters · filed 2026-03-30 | $435.75K derived: sum of 3 quarters · filed 2026-03-30 | $518.75K 10-K · filed 2026-03-30 |
| 2024-09-30 | $124.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $249.00K derived: sum of 2 quarters · filed 2025-11-13 | $332.00K 10-Q · filed 2025-11-13 | $554.50K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $124.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $207.50K 10-Q · filed 2025-08-14 | $430.00K derived: sum of 3 quarters · filed 2025-08-14 | $430.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $83.00K 10-Q · filed 2025-05-15 | $305.50K derived: sum of 2 quarters · filed 2025-05-15 | $305.50K derived: sum of 3 quarters · filed 2025-05-15 | $750.50K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $222.50K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-03 | $222.50K derived: sum of 2 quarters · filed 2025-04-03 | $667.50K derived: sum of 3 quarters · filed 2025-04-03 | $667.50K 10-K · filed 2025-04-03 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $445.00K derived: sum of 2 quarters · filed 2024-11-14 | $445.00K 10-Q · filed 2024-11-14 | $445.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $445.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $445.00K 10-Q · filed 2024-08-14 | $445.00K derived: sum of 3 quarters · filed 2024-08-14 | $445.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-14 | $0.00 derived: sum of 2 quarters · filed 2024-05-14 | $0.00 derived: sum of 3 quarters · filed 2024-05-14 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-15 | $0.00 derived: sum of 2 quarters · filed 2024-04-15 | $0.00 10-K · filed 2024-04-15 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |